What is OnCusp?
OnCusp Therapeutics operates as a global biopharmaceutical entity dedicated to the rigorous translation of first-in-class oncology assets. The company distinguishes itself through a focused portfolio strategy, bridging the gap between promising laboratory research and proven medical solutions. Led by a founding team with extensive expertise in business development and clinical trial execution, OnCusp is strategically positioned to navigate the complexities of drug discovery and regulatory approval. Its market position is defined by a commitment to high-impact therapeutic development, aiming to address significant unmet needs in cancer treatment through innovative science and operational excellence.
How much funding has OnCusp raised?
OnCusp has raised a total of $125M across 2 funding rounds:
Angel/Seed
$25M
Series A
$100M
Angel/Seed (2021): $25M with participation from BioTrack Capital, AIHC Capital, Sequoia Capital, and Oriza Seed Fund
Series A (2024): $100M led by BioTrack Capital, Novo Holdings, Catalio Capital Management, OrbiMed, F-Prime Capital Partners, and Marshall Wace
Key Investors in OnCusp
BioTrack Capital
A dedicated healthcare venture capital firm focused on building and incubating innovative life science companies, with a specific emphasis on the Chinese market.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, serving as a major institutional investor in the global life sciences sector.
Catalio Capital Management
A New York-based investment firm specializing in breakthrough biomedical technology, managing assets across private, public, and credit markets.
What's next for OnCusp?
Looking ahead, OnCusp is poised to leverage its recent capital to drive its lead assets through critical clinical milestones. The strategic focus will likely center on expanding its clinical development footprint and optimizing its research infrastructure to maintain a competitive edge in the oncology market. By maintaining a lean, high-expertise operational model, the company is expected to continue attracting top-tier institutional interest, further strengthening its balance sheet for future phases of growth. The emphasis remains on delivering measurable clinical outcomes that validate its proprietary research platform and enhance long-term shareholder value.
See full OnCusp company page
